.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on everyone market.The Eli Lilly-partnered biotech hopes to list on the Nasdaq under the icon "BIOA," depending on to documentations filed along with the Stocks and Substitution Commission. The provider has actually certainly not publicly shared an anticipated monetary quantity for the offering.The clinical-stage business promotes lead prospect azelaprag, an orally delivered tiny molecule slated to get in period 2 screening in combination along with semaglutide-- marketed through Novo Nordisk under brand name Wegovy for fat burning-- in the first one-half of next year. Semaglutide is actually also sold as Ozempic as well as Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is actually designed to integrate properly with GLP-1 drugs, boosting fat burning while preserving muscular tissue mass. The investigational drug was discovered to be well-tolerated amongst 265 individuals throughout eight period 1 trials, depending on to BioAge.Previously, BioAge got the assistance of Lilly to manage a test combining azelaprag with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes as Mounjaro and Zepbound for weight loss. The partners are presently performing a stage 2 trial of azelaprag and tirzepatide, with topline outcomes assumed in the 3rd quarter of 2025.The biotech is likewise organizing a blood insulin level of sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the very first half of next year to support prospective sign expansion. On top of that, the provider plans to talk to the FDA for consent in the 2nd one-half of 2025 to launch human screening for an NLRP3 inhibitor targeting metabolic conditions as well as neuroinflammation.BioAge's expected move to the general public market complies with a mild uptick in intended biotech IPOs coming from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the recent IPO landscape is actually a "blended photo," along with high-grade providers still debuting on the public markets, only in minimized numbers, depending on to PitchBook.